A number of firms have modified their ratings and price targets on shares of Ascentage Pharma Group International (NASDAQ: AAPG) recently:
- 10/16/2026 – Ascentage Pharma Group International is now covered by William Blair. They set an “outperform” rating on the stock.
- 10/14/2026 – Ascentage Pharma Group International is now covered by Citigroup Inc.. They set a “buy” rating and a $46.00 price target on the stock.
- 10/13/2026 – Ascentage Pharma Group International is now covered by Citigroup Inc.. They set a “buy” rating and a $46.00 price target on the stock.
- 10/13/2026 – Ascentage Pharma Group International is now covered by Citizens Jmp. They set a “market outperform” rating and a $35.00 price target on the stock.
- 10/8/2026 – Ascentage Pharma Group International had its price target lowered by JPMorgan Chase & Co. from $46.00 to $33.00. They now have an “overweight” rating on the stock.
- 8/21/2026 – Ascentage Pharma Group International had its “buy” rating reaffirmed by BTIG Research. They now have a $48.00 price target on the stock.
Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.
Featured Articles
- Five stocks we like better than Ascentage Pharma Group International
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for Ascentage Pharma Group International - Unsponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International - Unsponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
